Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive 52-week cardiorenal results from a pooled analysis from the inTandem1 and inTandem2 studies of Zynquista (sotagliflozin) in adults with type 1 diabetes.
Zynquista demonstrated changes in clinical biomarkers such as estimated glomerular filtration rate (eGFR), hematocrit, serum albumin, uric acid, systolic blood pressure and urinary albumin-to-creatinine ratio (UACR) that suggest Zynquista may reduce cardiovascular risk and progression of chronic kidney disease. Zynquista was associated with short- and long-term renal hemodynamic changes. Importantly, after cessation of 52 weeks of therapy, eGFR was comparable to baseline and significantly higher than placebo in Zynquista-treated patients.
These results were recently published in Diabetes Care, the ADA’s peer-reviewed research journal dedicated to diabetes treatment and prevention. The online publication, ‘The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults with Type 1 Diabetes’, may be accessed here https://doi.org/10.2337/dc19-0937.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.